Company profile: OnDosis
1.1 - Company Overview
Company description
- Provider of flexible, individualized dosing of oral medicines via a Dosage Manager delivering micro-unit forms (granules, pellets, mini-tablets) with accurate dosing, plus connected services: patient app, cloud platform, and physician interface for remote monitoring, adherence support, physician-patient communication, secure data exchange, regulatory compliance, and third-party integrations.
Products and services
- Dosage Manager: A micro‑unit–based device that dispenses oral solid prescription medicines—granules, pellets, or mini‑tablets—via a button press, ensuring accurate dose delivery for patient‑friendly administration
- Connected Services: An interoperable suite enabling remote patient monitoring, physician‑patient communication, and integration with third‑party technologies to architect comprehensive treatment management across the OnDosis digital ecosystem
- Physician Interface: A web-based application that lets healthcare providers access patient data, monitor medication adherence, and communicate with patients to improve care coordination and treatment oversight
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OnDosis
Aquarius Bio
HQ: United States
Website
- Description: Provider of a proprietary drug delivery platform to improve existing drugs, specializing in biotechnology, medicine, and pharmaceuticals.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aquarius Bio company profile →
EryDel
HQ: Italy
Website
- Description: Provider of red blood cell-based drug delivery technologies and therapies. Offers the AIDE platform for autologous intracellular drug encapsulation, the CE marked Red Cell Loader device and EryKit for point-of-care loading, and EryDex, a patient-specific dexamethasone sodium phosphate treatment for Ataxia-Telangiectasia; conducting the NEAT Phase 3 trial evaluating EryDex's neurological effects.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full EryDel company profile →
Medical International Technology
HQ: Canada
Website
- Description: Provider of needle-free jet injectors for human and animal vaccinations, developing, marketing, and distributing these devices.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Medical International Technology company profile →
TriSalus
HQ: United States
Website
- Description: Provider of novel infusion systems for the interventional radiology market, including Pressure-Enabled Drug Delivery to overcome intratumoral pressure and enhance local drug concentrations; an integrated platform combining immunomodulation therapy with proprietary intravascular regional delivery for liver and pancreatic tumors; and investigational TLR9 agonist nelitolimod (SD-101), evaluated in ongoing PERIO-01 and PERIO-02 clinical trials.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full TriSalus company profile →
Retractable Technologies
HQ: United States
Website
- Description: Provider of safety medical products for the healthcare profession, focused on automated needle retraction to reduce needlestick injuries. Offerings include VanishPoint syringes (including U-100 insulin), blood collection sets and tube holders, IV catheters, and EasyPoint retractable needles, with one-handed or in‑vein activation, accurate dose delivery, and reduced disposal space.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Retractable Technologies company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OnDosis
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OnDosis
2.2 - Growth funds investing in similar companies to OnDosis
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OnDosis
4.2 - Public trading comparable groups for OnDosis
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →